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Abstract
Rationale—The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa)
acquisition in children with cystic fibrosis (CF) is unknown.
Objectives—To determine if failure of antibiotic therapy to eradicate Pa and frequency of Pa
recurrence are associated with increased exacerbation risk.
Methods—The cohort included 282 children with CF who participated in the EPIC trial ages 1–
12 with newly acquired Pa, defined as either a first lifetime Pa positive respiratory culture or
positive after two years of negative cultures (past isolation of Pa but >2 years prior to the trial).
All received antibiotics to promote initial eradication followed by 15 months of intermittent
maintenance antibiotics. Quarterly cultures were used to define initial eradication success and
subsequent number of Pa recurrences. A standardized symptom-based definition of exacerbation
was utilized. Cox proportional hazards models were used to estimate exacerbation risk.
Results—Failure to initially eradicate Pa was associated with exacerbation risk (hazard ratio
[HR]: 2.49, 95% confidence interval [CI] 1.26,4.93). In 245/282 with successful initial eradication
during the trial, past isolation of Pa >2 years before the trial was the most significant predictor of
exacerbation (HR 1.62, 95% CI 1.12,2.35). In 37/282 who failed initial eradication, persistent Pa
during the maintenance phase (1 or more Pa recurrences after failure to initially eradicate) added
even greater exacerbation risk (HR 4.13, 95% CI 1.28, 13.32).
Conclusions—Children with CF who fail to eradicate after initial antibiotic treatment are at
higher risk of subsequent exacerbation, suggesting clinical benefit to successful early eradication
of Pa infection.
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Pseudomonas aeruginosa (Pa) is the most common pathogen in cystic fibrosis (CF) airway
disease, and after the establishment of chronic infection is associated with significant
morbidity and mortality1–10. Several studies have reported an association between new
acquisition of Pa in childhood and poorer clinical outcomes after several years when
compared to children who have not acquired Pa5–11, suggesting a more gradual worsening
of lung disease after Pa acquisition10,11. Whether Pa acquisition has significant impact on
shorter-term clinical outcomes remains an unanswered question.
The recently completed EPIC randomized clinical trial was designed to determine the
optimal anti-pseudomonal treatment strategy in children with CF who recently acquired Pa,
comparing the effectiveness of more aggressive versus less aggressive anti-pseudomonal
treatment on both clinical and microbiologic outcomes12. Specifically, the trial compared a
cycled treatment regimen administered on a quarterly basis regardless of Pa culture results
to a culture-based strategy in which treatment was administered on a quarterly basis only in
response to Pa positive respiratory cultures. No differences in the primary clinical and
microbiologic endpoints, time to pulmonary exacerbation and proportion of positive Pa
cultures, were identified between treatment strategies over the 18 month study period13.
The richness of data from the EPIC trial provides a unique opportunity to investigate other
clinically relevant questions such as the relationship between microbiologic outcomes and
pulmonary exacerbation in a cohort of children with newly acquired Pa. In addition to
frequent respiratory cultures and detailed microbiologic history since birth, a standardized,
symptom-based definition of pulmonary exacerbation was utilized in the trial. Further, strict
anti-pseudomonal treatment protocols for promoting initial Pa eradication and subsequent
maintenance were followed, enabling a comprehensive evaluation of the association
between newly acquired Pa and exacerbations in young children with CF in the presence of
contemporary treatment approaches. Using the cohort of children enrolled in the EPIC
clinical trial with recent new acquisition of Pa defined as either first documented lifetime Pa
or Pa after at least two years of negative cultures, the objective of our study was to evaluate
whether (1) past isolation of Pa (>2 years before enrollment), (2) failure to eradicate Pa
after initial antibiotics received during the trial, and (3) frequency of Pa recurrence are
associated with increased risk of a pulmonary exacerbation. Some of the results of this study
were previously reported in abstract form14.
Materials and Methods
Eligibility
Children with CF ages 1–12 years with newly acquired Pa within six months of enrollment
were eligible for the EPIC trial. Newly acquired Pa was defined as the first lifetime
documented Pa positive culture or a Pa positive culture after a two-year absence of Pa. For
children ages 12 to 15 months, at least one Pa positive culture since birth was required.
Other eligibility criteria have been previously reported12. All centers obtained institutional
review board approval, and parents or guardians provided informed consent.
Study Design
During the first quarter of the study, all children received initial Pa eradication treatment
consisting of 28–56 days of open label tobramycin inhalation solution (TIS, Novartis
Pharmaceutical Corp), with half of the children randomly assigned to a concurrent 14-day
course of oral ciprofloxacin (Bayer Healthcare AG) and half to oral placebo. Children were
randomized to one of two maintenance treatment strategies administered over the five
remaining quarters (15-months): (1) Cycled therapy: treatment provided in quarterly cycles
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regardless of findings from scheduled quarterly respiratory cultures, or (2) Culture-based
therapy: treatment only in response to identification of Pa from quarterly cultures.
Treatment administered during the 15-month maintenance phase in both arms consisted of
28 days open-label TIS with either a concurrent 14-day course of oral ciprofloxacin or
placebo as received during the first quarter (E-Figure 1 and E-Table 1, Online Supplement).
Pa culture status from birth was documented via medical records review. During the clinical
trial, oropharyngeal cultures were obtained during follow-up at weeks 10, 22, 34, 46, 58, and
70 in addition to expectorated sputum cultures if available (<4% of children had sputum
available at each visit). Pa culture results at week 10, obtained after antibiotic therapy
received during the first quarter, were used to define initial eradication success or failure.
All cultures were processed at the Center for CF Microbiology at Seattle Children’s Hospital
(Seattle, Washington) as previously described12. Assessment for a pulmonary exacerbation
was done at all scheduled study visits as well as acute illness visits. An a priori, established
definition of pulmonary exacerbation was used for the determination of these events (E-
Table 2, Online Supplement).
Statistical Analysis
Logistic regression was used to assess the association between baseline characteristics and
failure to initially eradicate newly acquired Pa after antibiotics received in the first quarter.
Cox proportional hazards regression was used to estimate associations of past isolation of
Pa, failure to initially eradicate, and number of Pa recurrences after initial antibiotics with
time to pulmonary exacerbation during the 15 month maintenance phase15. Number of Pa
recurrences after initial antibiotic therapy was treated as a time dependent covariate
throughout the maintenance phase. Potential confounders were assessed including age,
gender, body mass index (BMI), genotype classification16–18, and randomized treatment
assignment. Odds and hazard ratios from the models were presented with 95% confidence
intervals due to the exploratory nature of this study; a priori precision estimates for these
analyses are provided in the Supplement (E-Table 3). Analyses were performed using R
2.11.1 (R Foundation for Statistical Computing, Austria).
Results
Characteristics of the Study Cohort by Pa Status after Initial Antibiotic Therapy
A total of 282/304 (93%) participants in the EPIC clinical trial were included in the study
cohort, based on the availability of the initial eradication outcome at week 10. The 22
excluded children were similar to those included in the current analysis except for a slightly
younger age and lower BMI (see E-Table 4, Online Supplement). There were 245/282
(87%) who achieved successful initial eradication, and 37/282 children (13%) who failed to
eradicate recently acquired Pa at week 10. Baseline clinical and microbiologic
characteristics are described separately in Table 1 for these two subgroups. No significant
baseline clinical or microbiologic predictors of initial eradication success were identified.
Baseline and Initial Treatment Response Risk Factors for Exacerbation
A total of 44/282 (16%) participants met the a priori definition of pulmonary exacerbation
and were treated with intravenous (IV) antibiotics, and 139/282 (49%) met the a priori
definition of pulmonary exacerbation and were treated with antibiotics by any route of
administration (oral, inhaled, or IV) during the 15-month maintenance phase. The risk of
exacerbation in relation to baseline characteristics including past isolation of Pa (>2 years
before enrollment), initial antibiotic treatment regimen, and failure to eradicate were
evaluated. Table 2 displays the hazard ratios and corresponding confidence intervals
quantifying the univariate associations between each potential risk factor and both
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definitions of pulmonary exacerbation. Multivariable model development did not reveal
significant interactions or differing results as compared to these univariate results.
Among the baseline characteristics evaluated, past isolation of Pa was significantly
associated with an increased risk of an exacerbation. Children with past Pa as compared to
those never colonized with Pa had significantly increased risk of an exacerbation treated
with IV antibiotics (hazard ratio [HR] 2.12, 95% confidence interval [CI]: 1.17, 3.83) and
antibiotics by any route of administration (HR 1.51, 95% CI 1.07,2.12). No significant
changes in these estimates of risk were identified after adjusting for age which by definition
was highly correlated with past isolation of Pa. As seen in Table 2, age was not significantly
associated with exacerbation risk. Figure 1 (panels a and b) displays the corresponding
Kaplan-Meier plots for time to first exacerbation comparing those with first lifetime
documented Pa to those with a past isolation of Pa.
Failure to eradicate Pa after initial antibiotics received during the trial was significantly
associated with risk of exacerbation treated with IV antibiotics during the maintenance
phase (HR 2.49, 95% CI 1.26, 4.93), and with an elevated but not significant risk of
exacerbations treated with antibiotics by any route (HR 1.49, 95% CI 0.95, 2.36) (Table 2).
Figure 1 (panels c and d) displays the corresponding Kaplan-Meier plots for time to first
exacerbation comparing those who achieved initial eradication to those who failed. Of note,
there were 5/37 (14%) of children who failed to initially eradicate at week 10 who were
treated with inhaled or oral antibiotics for a pulmonary exacerbation at the time of failure to
eradicate. As displayed in Figure 1 (d), these 5 children were responsible for most of the risk
of exacerbations treated with antibiotics by any route among those who failed to initially
eradicate Pa. As seen in Table 2, no significant differences between treatment regimens in
the risk of exacerbation during the 15-month maintenance phase were found.
Association between Pa Recurrence during the Maintenance Phase and Risk of
Exacerbation
Pa recurrence rates, defined by the number of Pa positive cultures from week 10 to the end
of the 15-month maintenance phase, differed significantly between those who did and did
not achieve initial eradication (Figure 2). A total of 65/245 (27%) children who achieved
initial eradication at week 10 had at least one Pa positive culture during the maintenance
phase, while 21/37 (57%) children who failed initial eradication had at least one additional
Pa positive culture during the maintenance phase. Thus, the eradication outcome at Week 10
was significantly associated with subsequent Pa positivity over the remainder of the study
(OR: 3.6, 95% CI: 1.8, 7.4, E-Figure 2).
Because of the observed difference in Pa recurrence rates between children who achieved
initial eradication and those that failed, the association between the number of Pa
recurrences and exacerbations was separately evaluated for each of these subgroups.
Multivariable models were adjusted for past isolation of Pa, since this was found to be
significantly associated with exacerbation risk. No significant interactions between the
number of Pa recurrences and potential confounders, including treatment assignment, were
identified. Table 3 displays the final model results for children who achieved initial
eradication and those that failed.
Among those who achieved initial Pa eradication, past isolation of Pa was the most
significant predictor of exacerbation risk. There was no significant difference in risk of an
exacerbation comparing those who did and did not have recurrence of Pa during the
maintenance phase. In contrast, among the children who failed initial eradication, past
isolation of Pa was not significantly associated with risk of an exacerbation treated either
with IV antibiotics or antibiotics by any route. Persistent Pa, defined as at least one
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additional Pa positive culture after failure to eradicate, was significantly associated with a
an even greater risk of an exacerbation treated with antibiotics by any route but not with risk
of an exacerbation treated with IV antibiotics.
Discussion
We have identified key microbiologic risk factors associated with increased risk of a
pulmonary exacerbation after recent Pa acquisition treated with a standardized eradication
regimen. Specifically, those children who failed to eradicate Pa with initial antibiotic
treatment were at increased risk of a pulmonary exacerbation treated with IV antibiotics in
the subsequent 15 months. While the majority of children included in our study successfully
eradicated Pa after initial antibiotic therapy, the 13% that did not eradicate after initial
antibiotics represent a vulnerable subgroup more likely to have frequent Pa recurrence and
higher risk of a pulmonary exacerbation. Our eradication failure rates are comparable to
those reported in previous studies19–23, in particular to that observed in the recently
completed ELITE trial for which approximately 10% of 120 children had a positive Pa
culture or serologic response one month after completion of initial antibiotic therapy24.
Our study complements prior studies by focusing on shorter term risk of exacerbation over
15 months rather than risk over a several year period5,6. Our study evaluated two types of
exacerbations, both those treated with IV antibiotics and those treated with antibiotics by
any route of administration which enabled focus on the exacerbation definition independent
of how the physician decided to treat. Our study found notable differences in risk factors for
exacerbations between those with initial eradication success and failure. Past isolation of Pa
was a risk factor for subsequent exacerbations only among those who achieved initial
eradication. In contrast, Pa recurrence was a risk factor only among those who failed initial
eradication. Those with persistent Pa during the study are perhaps best characterized as
having emerging chronic infection as defined by respiratory cultures25, and for whom it is
no surprise has the greatest exacerbation risk. It will therefore be critical to further define the
transition between early and chronic Pa infection in young children with CF, and whether
failure to initially eradicate is indicative of this transition and thus the need for more
effective treatment approaches.
The exploratory nature of our study implies important key limitations that must be
considered. The study cohort was confined to children enrolled in the EPIC clinical trial and
thus our results may not be generalizable to the population of children with CF and newly
acquired Pa. The average FEV1% predicted in the older children at baseline was 96% with
no observed changes over the course of the study13, and thus represented a group with
relatively normal lung function. Thus, the duration of this study might not have been
sufficient to investigate the relationship between exacerbation events and decline in lung
function. Secondly, we must be careful to remember that associations may not be causal. For
instance, it may be that children who fail to eradicate are subject to more rigorous symptom
surveillance and thus there is an indication bias for the diagnosis of a pulmonary
exacerbation. It should be noted however that since pulmonary exacerbations comprised the
primary efficacy endpoint in the clinical trial, a rigorous surveillance was promoted among
all children enrolled in the trial regardless of treatment group and microbiologic status. In
addition, it is important to note that past isolation of Pa and failure to eradicate may simply
be markers for unmeasured characteristics which are more directly and causally related to
exacerbation risk, for example structural airway damage. Lastly, the precision for which we
can estimate associations in this study, particularly among those who failed to initially
eradicate Pa, is limited by both the size of the cohort and incidence of exacerbation events.
Thus, there may be important associations for which there was insufficient data to deem
statistically and clinically significant. Despite these limitations, the results of our study
Mayer-Hamblett et al. Page 5













provide a working hypothesis for the relative impact of lifetime history of Pa positivity,
failure to initially eradicate Pa, and Pa recurrence on the risk of a pulmonary exacerbation.
In summary, clinical and microbiologic data acquired during the EPIC clinical trial has
provided the opportunity to investigate the association between newly acquired Pa,
treatment response, and risk of pulmonary exacerbation in young children with CF. This
study identified a small but clinically important group of children with CF who fail to
achieve initial Pa eradication and who are at higher risk of exacerbation, and suggests
clinical benefit among those with successful initial eradication. Ongoing studies utilizing
banked sera and Pa isolates collected in the EPIC clinical trial will provide important
complementary data for determining whether there are bacterial phenotypic characteristics
or serologic markers that can further depict the association between early Pa infection
patterns and clinical outcome in children with CF. These findings may ultimately help to
identify high risk groups that will benefit from alternative antibiotic regimens targeted
towards Pa so that in the future, all children with CF will successfully eradicate this
bacterial pathogen.
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Kaplan Meier plot of time to first pulmonary exacerbation treated with either IV antibiotics
(a and c) or antibiotics by any route of administration (b and d), comparing those with newly
acquired Pa who entered the trial with no history of Pa colonization versus those who
entered with past isolation of Pa (>2 years prior to enrollment) (a and b), and those who
achieved successful initial eradication at week 10 to those who failed to achieve successful
initial eradication (c and d).
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Distribution of the number of Pa positive cultures from week 10 through the end of the 15-
month maintenance phase for subgroups defined by initial eradication success at week 10.
Mayer-Hamblett et al. Page 11

























Mayer-Hamblett et al. Page 12
Table 1
Baseline characteristics and initial antibiotic therapy received for newly acquired Pa comparing those who
achieved initial eradication of Pa at week 10 and those who failed to eradicate at week 10. Odds ratios are











Female, n (%) 16 (43) 129 (53) 0.69 0.34,1.38
Age in years, mean (SD) 5.8 (3.62) 5.8 (3.54) 1.00 0.91,1.10
FEV1 % predicted‡, mean (SD) 101.9 (19.04) 95.6 (16.44) 1.02 0.99, 1.06
BMI (kg/m2), mean (SD) 16.5 (1.79) 16.7 (1.84) 0.95 0.78,1.16
Genotype, n (%)
ΔF508 heterozygous 19 (51) 89 (36) -
ΔF508 homozygous 16 (43) 124 (51) 0.60 0.29,1.24
Other 2 (5) 20 (8) 0.47 0.10,2.18
Unknown 0 (0) 12 (5) NA
CFTR genotype class*, n (%)
A 25 (68) 188 (77) -
B 6 (16) 19 (8) 2.37 0.87,6.51
Unclassified 6 (16) 26 (11) 1.74 0.65,4.63
Unknown 0 (0) 12 (5) NA
Past isolation of Pa †, n (%) 13 (35) 81 (33) 1.10 0.53,2.27
Total number of Pa + cultures since birth, n (%)
1 24 (65) 164 (67) -
2 6 (16) 45 (18) 0.91 0.35,2.36
3 or more 7 (19) 36 (15) 1.33 0.53,3.32
S. aureus at baseline‡, n (%) 18 (49) 142 (60) 0.63 0.32,1.27
S. maltophila at baseline‡, n (%) 1 (3) 9 (4) 0.70 0.09,5.72
Initial Antibiotic Therapy for New Onset Pa
Antibiotics received during the trial, n (%)
TIS with placebo 17 (46) 128 (52) -























TIS with ciprofloxacin 20 (54) 117 (48) 1.29 0.64,2.57
TIS= Tobramycin inhalation solution; SD=Standard deviation; BMI = Body mass index; CI= Confidence Interval; Pa = P. aeuriginosa; S. aureus
= Staphylococcus aureus; S. maltophila = Stenotrophomonas maltophila.
*
Cystic fibrosis transmembrane conductance regulator (CFTR) mutations were classified based on functional class. Genotypes with both CFTR
mutations in functional classes I, II, or III (severely reduced CFTR function) were considered class A; genotypes with one or both mutant alleles in
class IV or class V (some residual CFTR function) were considered class B. Genotypes in which a functional class could not be assigned for one or
both alleles were considered unclassified15–17.
†
The positive Pa culture used for eligibility into the trial was newly acquired after a 2 year history of negative Pa cultures, and there was at least
one Pa positive culture prior to this window since birth.
‡
Baseline spriometry results were available for 17/37 older children who were Pa+ at week 10 and able to perform spirometry and 134/245 Pa−
children. Baseline microbiology results were available for 237/245 children who were Pa – at week 10.
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Table 3
Hazard ratios and 95% confidence intervals from multivariable, time dependent Cox proportional hazards
models used to assess whether Pa recurrence after initial antibiotic therapy is associated with the risk of (a)
pulmonary exacerbation treated with IV antibiotics, and (b) pulmonary exacerbation treated with antibiotics by
any route of administration. Models were adjusted for past isolation of Pa and generated separately for the
cohort who achieved successful eradication at week 10 and those who failed to achieve successful eradication
at week 10. No significant interactions were identified.
(a) PE Treated with
IV Antibiotics






Results for Cohort who Achieved Initial Pa Eradication (n=245)
Past isolation of Pa 2.62 1.31,5.22 1.62 1.12,2.35
Number of Pa recurrences after initial antibiotic therapy
0 - - - -
1 or more 1.19 0.45,3.20 1.23 0.70,2.16
Results for Cohort who Failed to Achieve Initial Pa Eradication (n=37)
Past isolation of Pa 0.89 0.26,3.09 0.83 0.34,2.01
Number of Pa recurrences after initial antibiotic therapy
1 - - - -
2 or more 2.66 0.72,9.87 4.13 1.28,13.32
PE= pulmonary exacerbation; Pa = P. aeruginosa; CI= confidence interval.
Pediatr Pulmonol. Author manuscript; available in PMC 2013 February 1.
